» Articles » PMID: 21425882

Optimal Frequency of Lithium Administration in the Treatment of Bipolar Disorder: Clinical and Dosing Considerations

Overview
Journal CNS Drugs
Specialties Neurology
Pharmacology
Date 2011 Mar 24
PMID 21425882
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Bipolar disorder is a recurrent chronic illness distinguished by periods of mania and depression. Lithium has been used for about 60 years as a 'mood stabilizer' for bipolar disorder with proven efficacy in preventing relapse of both mania and depression. Despite its long history and ongoing use in current management of bipolar disorder, the optimal dosing of lithium is still the subject of ongoing debate. This article aims to evaluate different dosing schedules, in the light of the unique pharmacokinetic and pharmacodynamic properties of lithium, as well as its adverse-effect and toxicity profiles. This is all the more important given the narrow therapeutic index of lithium. Current recommendations mostly advocate that lithium be administered in multiple daily doses. However, single daily or alternate daily schedules may be viable options for administration. Multiple daily schedules are thought to be advantageous in maintaining more constant plasma lithium concentrations than single daily regimens, which are associated with significant fluctuations throughout the day. When comparing these two schedules with respect to plasma lithium concentrations, adverse-effect profiles and recurrence of symptoms, there are no significant differences between the two regimens. In fact, a single daily regimen may have added advantages in reducing the risk of long-term renal damage and increasing compliance. The evidence for alternate daily dosing is somewhat varied with regard to symptom recurrence; however, this schedule has been shown to be associated with decreased adverse effects, and further research into this issue is therefore warranted. Presently, therefore, clinicians should consider single daily administration of lithium to potentially minimize adverse effects and enhance compliance.

Citing Articles

Neonatal Feeding Trajectories in Mothers With Bipolar Disorder Taking Lithium: Pharmacokinetic Data.

Imaz M, Langohr K, Torra M, Soy D, Garcia-Esteve L, Martin-Santos R Front Pharmacol. 2021; 12:752022.

PMID: 34630122 PMC: 8493120. DOI: 10.3389/fphar.2021.752022.


[Analysis of risk factors, etiology and treatment standard of lithium poisoning].

Haussmann R, Mudra T, Sauer C, von Bonin S, Donix M, Bauer M Nervenarzt. 2019; 91(1):57-63.

PMID: 30941458 DOI: 10.1007/s00115-019-0705-7.


Population pharmacokinetic modeling of sustained release lithium in the serum, erythrocytes and urine of patients with bipolar disorder.

Couffignal C, Bertrand J, Sportiche S, Jarroir M, El Balkhi S, Djebrani-Oussedik N Eur J Clin Pharmacol. 2018; 75(4):519-528.

PMID: 30554270 DOI: 10.1007/s00228-018-2605-3.


A Novel Neuroprotective Mechanism for Lithium That Prevents Association of the p75-Sortilin Receptor Complex and Attenuates proNGF-Induced Neuronal Death and .

Greenwood S, Montroull L, Volosin M, Scharfman H, Teng K, Light M eNeuro. 2018; 5(1).

PMID: 29349290 PMC: 5771681. DOI: 10.1523/ENEURO.0257-17.2017.


An Oldie but Goodie: Lithium in the Treatment of Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms.

Won E, Kim Y Int J Mol Sci. 2017; 18(12).

PMID: 29232923 PMC: 5751281. DOI: 10.3390/ijms18122679.


References
1.
Yatham L, Kennedy S, Schaffer A, Parikh S, Beaulieu S, ODonovan C . Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009; 11(3):225-55. DOI: 10.1111/j.1399-5618.2009.00672.x. View

2.
Ichim L, Berk M, Brook S . Lamotrigine compared with lithium in mania: a double-blind randomized controlled trial. Ann Clin Psychiatry. 2000; 12(1):5-10. DOI: 10.1023/a:1009066725103. View

3.
Wilkinson D, Holmes C, Woolford J, Stammers S, North J . Prophylactic therapy with lithium in elderly patients with unipolar major depression. Int J Geriatr Psychiatry. 2002; 17(7):619-22. DOI: 10.1002/gps.671. View

4.
Plenge P, Stensgaard A, JENSEN H, Thomsen C, Mellerup E, Henriksen O . 24-hour lithium concentration in human brain studied by Li-7 magnetic resonance spectroscopy. Biol Psychiatry. 1994; 36(8):511-6. DOI: 10.1016/0006-3223(94)90614-9. View

5.
Young W . Review of lithium effects on brain and blood. Cell Transplant. 2009; 18(9):951-75. DOI: 10.3727/096368909X471251. View